Ultromics

What Ultromics does

Ultromics pioneers precision heart failure detection through its groundbreaking platform, EchoGo®, which revolutionizes the diagnosis of heart failure using artificial intelligence and cardiac ultrasound. The technology empowers clinicians to make precise, efficient, and accurate assessments, drawing from the largest known heart disease dataset in echocardiography. Ultromics targets challenging cardiac diseases, starting with HFpEF and cardiac amyloidosis, to support timely diagnosis and early intervention. The platform integrates seamlessly into existing echo workflows, analyzing standard echocardiograms after acquisition and returning results into clinical systems. Ultromics has achieved FDA 510(k) clearance and Breakthrough Device Designation for its products, and has secured incremental reimbursement pathways through assigned CPT Category III codes.

Products

• EchoGo® Heart FailureAdvanced AI for identifying patients with Heart Failure with preserved Ejection Fraction (HFpEF) from routine echocardiograms. It is FDA 510(k) cleared and supported by CPT code 0932T for reimbursement.
• EchoGo® AmyloidosisAdvanced AI for screening patients for Cardiac Amyloidosis from routine echocardiograms. It is FDA 510(k) cleared.
• EchoGo®A platform that delivers AI models for detecting HFpEF and screening for cardiac amyloidosis through a single integrated workflow. It also helps improve core measurements such as EF and global longitudinal strain.

Key capabilities

• Advanced AI for identifying HFpEF and screening for cardiac amyloidosis
• Analyzes routine echocardiograms within existing workflows
• FDA 510(k) cleared
• Breakthrough Device Designation
• Incremental reimbursement pathway (CPT code 0932T for EchoGo® Heart Failure)
• Seamless integration with ultrasound and PACS environments
• Automated insights delivered through existing workflows
• AI findings returned directly into PACS, CVIS, and EMR systems
• Findings typically available within 20 minutes
• Compatible with existing ultrasound systems
• No changes to scanning protocols or acquisition workflows required
• No manual interaction required for AI analysis
• Secure and compliant (certified)
• No additional hardware or software interfaces needed
• No vendor lock-in, compatible with leading ultrasound vendors
• No additional IT burden
• EchoGo® score for assessing likelihood of heart failure

Use cases

• Identifying patients with HFpEF from routine echocardiograms
• Screening for cardiac amyloidosis from routine echocardiograms
• Supporting timely diagnosis and early intervention for heart failure
• Improving accuracy and reproducibility of cardiac function evaluations (e.g., EF, global longitudinal strain)
• Providing actionable insights for referring physicians to intervene in patient care
• Assessing patients with borderline or inconsistent echocardiogram parameters to determine likelihood of heart failure
• Integrating AI-powered HFpEF detection into routine care pathways
• Supporting physician interpretation and patient management decisions in complete transthoracic echocardiography (TTE)
• Supporting physician interpretation and patient management decisions in limited or follow-up TTE studies
• Supporting physician interpretation and patient management decisions in outpatient cardiovascular imaging
• Supporting physician interpretation and patient management decisions in inpatient echocardiography assessment

AI approach

Ultromics develops advanced AI models to analyze echocardiograms for the detection of heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. Their AI integrates into existing clinical workflows, analyzing standard echo studies after acquisition and returning results to PACS and EMR systems. The technology is built upon algorithms designed at the University of Oxford and has been clinically validated.

Tech named: Artificial Intelligence, Machine Learning

Industries served

• Hospitals and Health Care

What it says sets it apart

• Groundbreaking platform EchoGo® revolutionizing heart failure diagnosis
• Utilizes the largest known heart disease dataset in echocardiography
• Targets severely undiagnosed conditions like HFpEF and cardiac amyloidosis
• FDA 510(k) cleared and Breakthrough Device Designation
• First AI technologies in echocardiography to move from clinical validation into reimbursed clinical practice (CPT code 0932T)
• Seamless integration with existing clinical workflows without disruption
• Clinically validated performance supported by peer-reviewed studies and real-world practice
• Partnerships with leading organizations like Mayo Clinic, Johnson & Johnson, Pfizer, American Heart Association, and National Institute of Health
• Developed at the University of Oxford in partnership with the U.K.’s NHS
• Provides objective methods to reduce variability and measure EF consistently
• EchoGo® score provides clear sense of urgency for patient management

Funding rounds we track

From the AI funding tracker — rounds as reported by the linked publications.